Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs Twist Bioscience Corp — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $28.56, while Twist Bioscience Corp trades at $92.03 (market cap $5.77B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, Invesco DB Commodity Index Tracking Fund nearer its low. Which is the better fit depends on your goals.
| DBC | TWST | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $31.69 | $102.88 |
52-Week Low | $21.62 | $24.16 |
Market Cap | — | $5.77B |
Enterprise Value | — | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC, the Invesco DB Commodity Index Tracking ETF, trades at $28.33, up 2.94% today, with a bullish technical signal from moving averages and oscillators. Recent news highlights its role as an inflation hedge, with a 52-week high noted in April 2026. The ETF provides diversified commodity exposure, benefiting from oil supply shocks and safe-haven demand, though key financial ratios like P/E and P/S are not applicable for this fund structure.
Outlook remains positive due to strong momentum and inflation hedging appeal, but risks include commodity price volatility and geopolitical factors. Analyst sentiment is supportive, with the ETF favored in balanced portfolios for moderate-risk investors seeking commodity diversification amid market uncertainty.
TWST trades at $90.35, down 0.31% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels near key support at $89. Revenue growth remains strong, reaching $376.57M in 2025, though the company continues to report net losses. Recent news highlights AI-driven drug discovery collaborations and insider selling activity, while analyst consensus leans bullish with a $91.63 price target.
The stock offers growth exposure to synthetic biology and AI-enabled therapeutics, but carries significant risk due to persistent negative cash flow and profitability challenges. Investor sentiment is cautiously optimistic, balancing innovation potential against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
